These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 23390943)
1. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum. Bern EM; Bousvaros A Expert Rev Clin Immunol; 2013 Feb; 9(2):117-27. PubMed ID: 23390943 [TBL] [Abstract][Full Text] [Related]
2. The risks and benefits of early immunosuppression and biological therapy. Sands BE Dig Dis; 2012; 30 Suppl 3():100-6. PubMed ID: 23295699 [TBL] [Abstract][Full Text] [Related]
3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
4. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
5. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Kwon JH; Farrell RJ Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323 [TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Shah SB; Hanauer SB Rev Gastroenterol Disord; 2008; 8(3):159-68. PubMed ID: 18957923 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic problems and advances in inflammatory bowel disease. Odze R Mod Pathol; 2003 Apr; 16(4):347-58. PubMed ID: 12692200 [TBL] [Abstract][Full Text] [Related]
13. [Idiopathic inflammatory bowel disease--prediction and treatment]. Lukás K Cas Lek Cesk; 2011; 150(6):315-20. PubMed ID: 21751503 [TBL] [Abstract][Full Text] [Related]
14. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. Subramaniam K; D'Rozario J; Pavli P J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824 [TBL] [Abstract][Full Text] [Related]
15. Severe complications of inflammatory bowel disease. Marrero F; Qadeer MA; Lashner BA Med Clin North Am; 2008 May; 92(3):671-86, ix. PubMed ID: 18387381 [TBL] [Abstract][Full Text] [Related]
16. Update of the management of inflammatory bowel disease. Fell JM Arch Dis Child; 2012 Jan; 97(1):78-83. PubMed ID: 21505142 [TBL] [Abstract][Full Text] [Related]